New dimensions in the pharmacologic treatment of schizophrenia and related psychoses

Peter F Buckley

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

During the past 5 years unprecedented advances have taken place in the psychopharmacology of schizophrenia and related psychoses. Clozapine and risperidone, two prototypic novel antipsychotic drugs, have had a significant impact on the treatment of psychotic disorders. Additionally, they have ushered in another generation of antipsychotic drugs with complex pharmacologic profiles, potentially enhanced efficacy, and more benign side- effect profiles than previously associated with conventional antipsychotic medications. This review highlights these developments, implications for the management of psychotic disorders, and the use of novel antipsychotic drugs in specific clinical subgroups.

Original languageEnglish (US)
Pages (from-to)363-378
Number of pages16
JournalJournal of Clinical Pharmacology
Volume37
Issue number5
DOIs
StatePublished - Jan 1 1997

Fingerprint

Psychotic Disorders
Antipsychotic Agents
Schizophrenia
Psychopharmacology
Risperidone
Clozapine

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

New dimensions in the pharmacologic treatment of schizophrenia and related psychoses. / Buckley, Peter F.

In: Journal of Clinical Pharmacology, Vol. 37, No. 5, 01.01.1997, p. 363-378.

Research output: Contribution to journalReview article

@article{7bb79b5cd18042f4adbc5d901214650e,
title = "New dimensions in the pharmacologic treatment of schizophrenia and related psychoses",
abstract = "During the past 5 years unprecedented advances have taken place in the psychopharmacology of schizophrenia and related psychoses. Clozapine and risperidone, two prototypic novel antipsychotic drugs, have had a significant impact on the treatment of psychotic disorders. Additionally, they have ushered in another generation of antipsychotic drugs with complex pharmacologic profiles, potentially enhanced efficacy, and more benign side- effect profiles than previously associated with conventional antipsychotic medications. This review highlights these developments, implications for the management of psychotic disorders, and the use of novel antipsychotic drugs in specific clinical subgroups.",
author = "Buckley, {Peter F}",
year = "1997",
month = "1",
day = "1",
doi = "10.1002/j.1552-4604.1997.tb04314.x",
language = "English (US)",
volume = "37",
pages = "363--378",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "5",

}

TY - JOUR

T1 - New dimensions in the pharmacologic treatment of schizophrenia and related psychoses

AU - Buckley, Peter F

PY - 1997/1/1

Y1 - 1997/1/1

N2 - During the past 5 years unprecedented advances have taken place in the psychopharmacology of schizophrenia and related psychoses. Clozapine and risperidone, two prototypic novel antipsychotic drugs, have had a significant impact on the treatment of psychotic disorders. Additionally, they have ushered in another generation of antipsychotic drugs with complex pharmacologic profiles, potentially enhanced efficacy, and more benign side- effect profiles than previously associated with conventional antipsychotic medications. This review highlights these developments, implications for the management of psychotic disorders, and the use of novel antipsychotic drugs in specific clinical subgroups.

AB - During the past 5 years unprecedented advances have taken place in the psychopharmacology of schizophrenia and related psychoses. Clozapine and risperidone, two prototypic novel antipsychotic drugs, have had a significant impact on the treatment of psychotic disorders. Additionally, they have ushered in another generation of antipsychotic drugs with complex pharmacologic profiles, potentially enhanced efficacy, and more benign side- effect profiles than previously associated with conventional antipsychotic medications. This review highlights these developments, implications for the management of psychotic disorders, and the use of novel antipsychotic drugs in specific clinical subgroups.

UR - http://www.scopus.com/inward/record.url?scp=0030946974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030946974&partnerID=8YFLogxK

U2 - 10.1002/j.1552-4604.1997.tb04314.x

DO - 10.1002/j.1552-4604.1997.tb04314.x

M3 - Review article

C2 - 9156369

AN - SCOPUS:0030946974

VL - 37

SP - 363

EP - 378

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 5

ER -